These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34480554)

  • 1. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
    Jayaraman S; Reid JM; Hawse JR; Goetz MP
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal and Uterotrophic Effects of Endoxifen in Female Rats.
    Gingery A; Iwaniec UT; Subramaniam M; Turner RT; Pitel KS; McGovern RM; Reid JM; Marler RJ; Ingle JN; Goetz MP; Hawse JR
    Endocrinology; 2017 Oct; 158(10):3354-3368. PubMed ID: 28977607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
    Jayaraman S; Hou X; Kuffel MJ; Suman VJ; Hoskin TL; Reinicke KE; Monroe DG; Kalari KR; Tang X; Zeldenrust MA; Cheng J; Bruinsma ES; Buhrow SA; McGovern RM; Safgren SL; Walden CA; Carter JM; Reid JM; Ingle JN; Ames MM; Hawse JR; Goetz MP
    Breast Cancer Res; 2020 May; 22(1):51. PubMed ID: 32430040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
    Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
    Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
    Goetz MP; Suman VJ; Reid JM; Northfelt DW; Mahr MA; Ralya AT; Kuffel M; Buhrow SA; Safgren SL; McGovern RM; Black J; Dockter T; Haddad T; Erlichman C; Adjei AA; Visscher D; Chalmers ZR; Frampton G; Kipp BR; Liu MC; Hawse JR; Doroshow JH; Collins JM; Streicher H; Ames MM; Ingle JN
    J Clin Oncol; 2017 Oct; 35(30):3391-3400. PubMed ID: 28854070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens.
    Hawse JR; Subramaniam M; Cicek M; Wu X; Gingery A; Grygo SB; Sun Z; Pitel KS; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC
    PLoS One; 2013; 8(1):e54613. PubMed ID: 23382923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer.
    Zhang C; Zhong Q; Zhang Q; Zheng S; Miele L; Wang G
    Breast Cancer Res Treat; 2015 Jul; 152(2):283-91. PubMed ID: 26071758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
    Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of
    Lin FI; Gonzalez EM; Kummar S; Do K; Shih J; Adler S; Kurdziel KA; Ton A; Turkbey B; Jacobs PM; Bhattacharyya S; Chen AP; Collins JM; Doroshow JH; Choyke PL; Lindenberg ML
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):500-508. PubMed ID: 27872957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
    Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
    Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.
    Maximov PY; McDaniel RE; Fernandes DJ; Korostyshevskiy VR; Bhatta P; Mürdter TE; Flockhart DA; Jordan VC
    Br J Pharmacol; 2014 Dec; 171(24):5624-35. PubMed ID: 25073551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
    Lim YC; Desta Z; Flockhart DA; Skaar TC
    Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
    Johnson MD; Zuo H; Lee KH; Trebley JP; Rae JM; Weatherman RV; Desta Z; Flockhart DA; Skaar TC
    Breast Cancer Res Treat; 2004 May; 85(2):151-9. PubMed ID: 15111773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.
    MacLeod AK; McLaughlin LA; Henderson CJ; Wolf CR
    Drug Metab Dispos; 2017 Jan; 45(1):17-22. PubMed ID: 27756789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
    Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
    Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen to raloxifene and beyond.
    O'Regan RM; Jordan VC
    Semin Oncol; 2001 Jun; 28(3):260-73. PubMed ID: 11402436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
    Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
    BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
    Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
    J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.
    de Vries Schultink AH; Alexi X; van Werkhoven E; Madlensky L; Natarajan L; Flatt SW; Zwart W; Linn SC; Parker BA; Wu AH; Pierce JP; Huitema AD; Beijnen JH
    Breast Cancer Res Treat; 2017 Feb; 161(3):567-574. PubMed ID: 28005246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.